Korean biosimilar giant Celltrion announced on Wednesday that it will present its vision and strategy for novel drug development at the 43rd JP Morgan Healthcare Conference next week.

The event, recognized as the world’s largest healthcare investment symposium, is set to take place Monday through Thursday in San Francisco, California. Over 8,000 participants and 550 biotech companies have reportedly been registered for the four-day event.

Celltrion Group Founder and Chairman Seo Jung-jin, along with CEO Seo Jin-seok, the founder’s eldest son, will outline a detailed roadmap for the novel drug pipeline during a presentation on Tuesday at the Grand Ballroom of the Westin St. Francis Hotel. Following the presentation, a Q&A session with investors will provide further insights into the company's plans.

The presentation will be featured on the conference’s main track stage, a platform reserved for companies noted for their industry significance and growth potential.

Building on its position as a trailblazer in antibody biosimilars, Celltrion has expanded into advanced therapeutic modalities, including antibody-drug conjugates and multi-specific antibodies.

At the conference, the company will share a detailed timeline for developing 13 innovative drugs—9 ADCs and 4 multi-specific antibodies—through 2028, including the planned IND filing schedules for each pipeline.

Key updates will highlight two oncology drugs, CT-P70 and CT-P71, which were first introduced at last year’s World ADC conference, alongside strategies to lead the advancement of next-generation ADCs and multispecific antibody therapeutics.

Celltrion has reiterated its commitment to a "dual-track approach," focusing on both biosimilar products and innovative drug development to ensure sustainable growth.

"At the conference, we will present our roadmap for evolving into a global leader in innovative pharmaceuticals," a Celltrion official said. "Leveraging our expertise as a pioneer in antibody technologies, we are dedicated to establishing ourselves as a key player in novel drug development."

To support this objective, the company announced at its Investor Day in Hong Kong last year that it plans to generate 40 percent of its revenue from innovative drugs by 2030.

By Kim Hae-yeon (hykim@heraldcorp.com)